Key Findings
The Europe contraceptive market is estimated to grow from $XX billion in 2018 to $xx billion by 2027, at a CAGR of 6.61% between 2019 and 2027. Germany dominated the overall market in terms of revenue in 2018, and Italy is expected to be the fastest growing market over the forecast period.

Market Insights
Germany, Italy, Spain, France, the United Kingdom and the remaining countries collectively forming the Rest of Europe regional segment are the major revenue contributors to the Europe market. In Italy, contraception, emergency contraception, and interruption of pregnancy are regulated by the laws that allow the possibility of contraceptive prescription to minors and further regulates the institution of family health centers as places aiming to promote women’s and children’s health. These laws and incentive enhance the market growth proficiently in the region.

Competitive Insights
Church & Dwight Co., Inc., Merck & Co., Inc., Mayer Laboratories, Inc., Pfizer, Inc., Pregna, Agile Therapeutics, Apothecus Pharmaceutical Corporation, Teva Pharmaceutical Industries Ltd., OCON Medical Ltd., Afaxys, Inc., Allergan Inc., Bayer AG, Okamoto Industries, Inc., Cooper Surgical Inc., and Reckitt Benckiser PLC are the major companies that have been extensively profiled in the report.